Anti-cancer activity of pegylated liposomal trans-anethole on breast cancer cell lines MCF-7 and T47D

Biotechnol Lett. 2015 Jul;37(7):1355-9. doi: 10.1007/s10529-015-1813-5. Epub 2015 Mar 20.

Abstract

Objective: To examine the role of liposomes for the encapsulation of drugs and their suitability for chemotherapy of breast cancer.

Results: Pegylated liposomal trans-anethole nanoparticles were synthesized through a reverse-phase evaporation technique. Nanoparticles were characterized in terms of mean diameter, size distribution, zeta potential, encapsulation and drug loading efficiency, drug release pattern and cytotoxicity effects. Size and zeta potential of pegylated nanoliposomal drug and blank pegylated nanoliposomal were 257 nm and -28 mV; 35.7 nm and -21 mV, respectively. Encapsulation and drug loading efficiency were 78 ± 2.5 and 2.3 ± 4.1 %, respectively. There was a 57 % release of trans-anethole from pegylated liposomal nanoparticles in 48 h. Compared to free drug, toxicological studies indicated around 9- and 8-fold cytotoxicity effect against MCF-7 and T47D cell lines respectively.

Conclusions: PEG-liposomes provided a high stability and slow release of trans-anethole in two cancer cell lines.

MeSH terms

  • Allylbenzene Derivatives
  • Anisoles / chemistry*
  • Anisoles / pharmacokinetics
  • Anisoles / pharmacology*
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / pharmacology*
  • Breast Neoplasms / metabolism*
  • Cell Survival / drug effects
  • Drug Delivery Systems
  • Female
  • Humans
  • Liposomes / chemistry*
  • MCF-7 Cells
  • Polyethylene Glycols / chemistry

Substances

  • Allylbenzene Derivatives
  • Anisoles
  • Antineoplastic Agents
  • Liposomes
  • Polyethylene Glycols
  • anethole